Skip to main content
Create Account
Training Center
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Insights
- Treatises
Forms & Checklists
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Developments in Pharmaceutical and Biotech Patent Law 2009
Chair(s):
David K. Barr, Daniel L. Reisner
Practice Area:
Biotechnology,
Intellectual property,
Life sciences,
Patent applications,
Patents,
Pharmaceuticals
Published:
Sep 2009
i
Other versions can be found in the
Related Items
tab.
ISBN:
9781402412691
PLI Item #:
19017
CHB Spine #:
G980
This version is not current.
Click here for the most recent version.
Search
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. Patentability of Active Pharmaceutical Ingredients
Chapter 2. Inequitable Conduct in Biotechnology and Pharmaceutical Patent Cases
Chapter 3. Recent Federal Circuit Cases on Written Description and Enablement
Chapter 4. Developments in Section 112 Law: The Enablement and Written Description Requirements As Applied to Pharma and Biotech Patents, Excerpted from Pharmaceutical and Biotech Patent Law
Chapter 5. What Is As Important As the KSR Analysis? We Still Need to Meet the Written Description and Utility Requirements in the Patent Office
Chapter 6. From MPEP 2163—Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, Para. 1, “Written Description” Requirement
Chapter 7. From MPEP 2107—Guidelines for the Examination of Applications for Compliance with the Utility Requirement: 2107.01 General Principles Governing Utility Rejections [R-5]-2100 Patentability
Chapter 8. The Impact of KSR on the Examination of Pharmaceutical and Biotech Patent Applications in the USPTO
Chapter 9. Issues in Pharmaceutical Patent Licensing
Chapter 10. The Antitrust Analysis of Pharmaceutical Patent Litigation Settlements
Chapter 11. Authorized Generics: An Interim Report, Federal Trade Commission Report, June
Index
About Us